Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amneal Pharmaceuticals (AMRX)

Amneal raises 2026 guidance as Q2 net revenue rises 10% to $796 million

Positive Impact 4 of 5 earnings Written later

Amneal reported second-quarter 2026 net revenue of $796 million, up 10% from $725 million a year earlier, and GAAP net income attributable to the company of $58 million, up from $22 million. The company raised its full-year 2026 guidance for net revenue, adjusted EBITDA and adjusted diluted EPS, and said a July term loan repricing is expected to cut annual cash interest by about $12 million.

Key points

  • Q2 2026 net revenue was $796 million, up 10%; Specialty rose 17%, Affordable Medicines rose 13%, and AvKARE fell 4%.
  • GAAP diluted EPS was $0.18 versus $0.07 a year earlier; adjusted diluted EPS was $0.30 versus $0.25, up 20%.
  • Adjusted EBITDA was $206 million, up 12% from the second quarter of 2025.
  • 2026 guidance raised: net revenue $3.10 billion to $3.20 billion (prior $3.05 billion to $3.15 billion); adjusted diluted EPS $0.96 to $1.06 (prior $0.95 to $1.05).

The filing

CompanyAmneal Pharmaceuticals (AMRX)
Form8-K, current report
Filed with the SECJul 30, 2026, 6:15 AM ET
Accession number0001723128-26-000025

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:58 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.